Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease
- PMID: 12531514
- DOI: 10.1016/s0169-328x(02)00488-6
Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease
Abstract
The abnormal hyperphosphorylation of tau in Alzheimer's disease (AD) has been proposed to involve the extracellular-signal-regulated protein kinase (ERK) of the mitogen-activated protein (MAP) kinase family. ERK is phosphorylated and thereby activated by MAP kinase kinase (MEK). In the present study, we determined the intracellular and regional distribution of the active forms of both MEK1/2 and ERK1/2, i.e. p-MEK1/2 and p-ERK1/2 in the entorhinal, hippocampal, and temporal cortices of 49 brains staged for neurofibrillary changes according to Braak and Braak's protocol. We found that p-MEK1/2 and p-ERK1/2 were present in the initial stages of neurofibrillary degeneration in the projecting neurons in the transentorhinal region, and extended into other brain regions co-incident with the progressive sequence of neurofibrillary changes up to and including Braak stage VI. It appeared that the accumulation of p-MEK1/2 and p-ERK1/2 was initiated in the cytoplasm of pretangle neurons in varying size granules, which grew into large aggregates co-existing with the progressive development of neurofibrillary tangles. Accumulation of p-MEK1/2 and p-ERK1/2 was found in cases with stages I-III neurofibrillary degeneration, which were devoid of amyloid deposition. These data provide direct in situ evidence consistent with the possible involvement of MAP kinase pathway in the hyperphosphorylation of tau and the presence of this lesion before deposition of beta-amyloid in AD.
Similar articles
-
Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.Brain Pathol. 2001 Apr;11(2):144-58. doi: 10.1111/j.1750-3639.2001.tb00387.x. Brain Pathol. 2001. PMID: 11303790 Free PMC article.
-
Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease.Am J Pathol. 2003 Sep;163(3):845-58. doi: 10.1016/S0002-9440(10)63445-1. Am J Pathol. 2003. PMID: 12937126 Free PMC article.
-
Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease.Am J Pathol. 2003 Aug;163(2):591-607. doi: 10.1016/S0002-9440(10)63687-5. Am J Pathol. 2003. PMID: 12875979 Free PMC article.
-
Tau therapeutic strategies for the treatment of Alzheimer's disease.Curr Top Med Chem. 2006;6(6):579-95. doi: 10.2174/156802606776743057. Curr Top Med Chem. 2006. PMID: 16712493 Review.
-
The Role of ERK1/2 Pathway in the Pathophysiology of Alzheimer's Disease: An Overview and Update on New Developments.Cell Mol Neurobiol. 2023 Jan;43(1):177-191. doi: 10.1007/s10571-022-01191-x. Epub 2022 Jan 17. Cell Mol Neurobiol. 2023. PMID: 35038057 Free PMC article. Review.
Cited by
-
Patient-Derived Fibroblasts With Presenilin-1 Mutations, That Model Aspects of Alzheimer's Disease Pathology, Constitute a Potential Object for Early Diagnosis.Front Aging Neurosci. 2022 Jul 1;14:921573. doi: 10.3389/fnagi.2022.921573. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35847683 Free PMC article.
-
Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation.Hum Mol Genet. 2011 Dec 15;20(24):4947-77. doi: 10.1093/hmg/ddr432. Epub 2011 Sep 23. Hum Mol Genet. 2011. PMID: 21949350 Free PMC article.
-
Heat shock protein 90 in Alzheimer's disease.Biomed Res Int. 2014;2014:796869. doi: 10.1155/2014/796869. Epub 2014 Oct 13. Biomed Res Int. 2014. PMID: 25374890 Free PMC article. Review.
-
Study on the mechanism of Xanthoceras sorbifolia Bunge oil in the treatment of Alzheimer's disease by an integrated "network pharmacology-metabolomics" strategy.Ann Med. 2025 Dec;57(1):2499700. doi: 10.1080/07853890.2025.2499700. Epub 2025 May 8. Ann Med. 2025. PMID: 40340504 Free PMC article.
-
Anesthesia induces phosphorylation of tau.J Alzheimers Dis. 2009;16(3):619-26. doi: 10.3233/JAD-2009-1003. J Alzheimers Dis. 2009. PMID: 19276556 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous